BlossomHill Therapeutics (BLSM) prices IPO at $16, raising $150M
As seen on the 24/7 Wall St. homepage on August 7, 2026.
Priced at $16 for a $150M Nasdaq debut
BlossomHill Therapeutics priced its IPO at $16 a share, raising $150 million with J.P. Morgan and Leerink leading the book. A deal that size for a precision oncology developer is a real test of how far the reopened biotech window extends.
Continue ReadingShow less
BlossomHill Therapeutics sold 9,375,000 shares at $16 each in its Nasdaq debut, bringing in $150 million in a deal led by J.P. Morgan and Leerink. The two underwriters are a familiar pairing in biotech capital raises, with Leerink's sector-specific focus lending credibility to the book-building process for a precision oncology story.
The $150 million raise is a meaningful data point for the broader biotech IPO market, which has been cautiously reopening after a prolonged drought. A deal of this size for an early-stage oncology developer signals that institutional investors are willing to put real capital behind the right science, but it also sets a high bar for BlossomHill to demonstrate clinical progress once it begins trading under the ticker BLSM.
Sponsored
Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. See the full list FREE now.
Investors watching the biotech window will want to track how BLSM trades in its first sessions relative to the $16 offer price. Sustained trading above the issue price would reinforce confidence that the window remains open for similarly sized precision medicine deals, while a break below it could prompt underwriters to price future oncology IPOs more conservatively.
Mentioned: BLSM